Degenerative Disc Disease Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Degenerative Disc Disease Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

 

DelveInsight’s “Degenerative Disc Disease Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Degenerative Disc Disease, historical and forecasted epidemiology as well as the Degenerative Disc Disease market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Unlock detailed insights into the Degenerative Disc Disease Market by downloading the comprehensive report from DelveInsight @ Degenerative Disc Disease Treatment Market Size

 

Key Takeaways from the Degenerative Disc Disease Market Report

• In September 2024:- VIVEX Biologics Inc.- The study is a randomized, double-blind, sham-controlled, multi-center study in participants with symptomatic lumbar intervertebral disc degeneration (> 6 months) and unresponsive to conservative therapy for at least 3 months. Participants will be randomized on a 1:1 basis to receive either a single VIA Disc NP intradiscal injection at 1 or 2 levels or a sham procedure at 1 or 2 levels.
• In September 2024:- Sclnow Biotechnology Co., Ltd.- In order to initially observe the safety and effectiveness of human umbilical cord mesenchymal stem cells (hUC-MSCs) transplantation in the treatment of lumbar disc degeneration, this project planned to include a single group of 20 patients with lumbar disc herniation, and adopt an open study design of non-random, self-controlled, single-dose group, and locally inject 2mL hUcMSCs into the lumbar disc of enrolled patients.
• DelveInsight’s epidemiology model estimates that there were approximately 73 million prevalent cases of Chronic Low Back Pain (CLBP) in the 7MM in 2023, with nearly 64 million diagnosed cases. This number is projected to rise throughout the forecast period (2024-2034).
• In 2023, the US had the highest number of diagnosed prevalent cases of DDD, with nearly 13 million cases. This figure is expected to rise by 2034.
• Among EU4 and the UK, the UK reported the highest number of diagnosed prevalent cases of DDD in 2023, with approximately 2.1 million cases. Germany closely followed with nearly 2 million cases, while Italy had the lowest at around 1 million.
• In 2023, the age-specific diagnosed prevalent cases of DDD in the 7MM showed notable trends: approximately 2.53 million cases for ages 18-29 years, 3.48 million for 30-39 years, 4.16 million for 40-49 years, and a peak of 5.14 million for 50-59 years. Cases were around 5.07 million in the 60-69 years group, 3.34 million for 70-79 years, and approximately 1.88 million for those aged 80 years and above.
• As per DelveInsight’s analysis, the US recorded approximately 32 million diagnosed prevalent cases of chronic low back pain (CLBP) in 2023. This number is expected to rise significantly during the forecast period from 2024 to 2034, driven by factors such as lifestyle changes, increasing obesity rates, and insufficient physical activity. These trends highlight the pressing need for targeted interventions aimed at addressing lifestyle-related issues to improve patient outcomes and reduce the burden of CLBP.
• The leading Degenerative Disc Disease Companies such as Mesoblast, Ltd., Grünenthal, DiscGenics, Inc., Spine Biopharma, Yuhan Corp, BioRestorative Therapies, AnGes, Inc., Shionogi & Co., Ltd., Kuros Biosurgery AG, Creative Medical Technology Holdings Inc., Stayble Therapeutics, Citospin, and others.
• Promising Degenerative Disc Disease Therapies such as Rexlemestrocel-L (MPC-06-ID), IDCT (Rebonuputemcel), SB-01 (Peniel2000/P2K, YH14618), BRTX-100, AMG0103 (NF-κB decoy oligonucleotide), and others.

 

Gain a competitive edge in the Degenerative Disc Disease Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Degenerative Disc Disease Treatment Drugs

 

Degenerative Disc Disease Epidemiology Segmentation in the 7MM

• Total Degenerative Disc Disease Diagnosed Prevalent Cases
• Degenerative Disc Disease Gender-specific Diagnosed Prevalent Cases
• Degenerative Disc Disease Age-specific Diagnosed Prevalent Cases

 

Degenerative Disc Disease Market Insights

Degenerative Disc Disease (DDD) primarily impacts the intervertebral discs, which serve as shock absorbers between the vertebrae of the spine. With time, these discs may deteriorate, resulting in pain, stiffness, and overall discomfort. While DDD is a natural consequence of aging, factors such as genetics, smoking, and repetitive stress can expedite the degenerative process. The main objective in treating DDD is to alleviate symptoms, especially pain, enhance overall function, and halt further degeneration of the intervertebral discs. Although complete reversal of disc degeneration is unlikely, the emphasis is on improving the individual’s quality of life by reducing pain, increasing mobility, and maximizing spinal functionality. Treatment strategies typically involve a blend of non-pharmacologic interventions, lifestyle changes, and, in certain cases, surgical options, tailored to the severity and unique characteristics of each patient’s condition.

 

Discover key developments and opportunities in the Degenerative Disc Disease Market. Click here to learn more from DelveInsight’s latest report @ Degenerative Disc Disease Market Size

 

Degenerative Disc Disease Treatment Market Landscape

The Degenerative Disc Disease treatment market landscape is rapidly evolving, offering a spectrum of options from conservative measures like physical therapy and lifestyle changes to invasive procedures such as spinal fusion and artificial disc replacement. Recent advancements in minimally invasive techniques and regenerative medicine, including intradiscal pharmacologic treatments like Spine BioPharm’s SB-01, present promising alternatives that may fill the gap between conservative care and major surgery. However, significant unmet needs remain, especially concerning the long-term effectiveness of current treatments and the high costs associated with surgical interventions. There is an increasing demand for effective non-surgical options that can deliver lasting relief and enhance quality of life without the risks and expenses tied to traditional surgical methods. Addressing these gaps is essential for improving patient outcomes and satisfaction in DDD management.

 

Degenerative Disc Disease Emerging Therapies

• SB-01: Spine Biopharma
• Rexlemestrocel-L (MPC-06-ID): Mesoblast/Grünenthal
• IDCT (rebonuputemcel): DiscGenics

 

Degenerative Disc Disease Market Outlook

The primary treatment goal for DDD is to manage symptoms, particularly pain, improve overall function, and prevent further degeneration of the intervertebral discs. While complete reversal of disc degeneration may not be achievable, the focus is on enhancing the individual’s quality of life by minimizing pain, improving mobility, and optimizing the overall functionality of the spine. Treatment approaches often involve a combination of non-pharmacologic interventions, lifestyle modifications, and, in some cases, surgical options, depending on the severity and specific characteristics of the condition in each patient.

 

Download DelveInsight’s Degenerative Disc Disease Market report today and stay ahead in this rapidly evolving field. @ Degenerative Disc Disease Clinical Trials

 

Scope of the Degenerative Disc Disease Market Report

• Coverage- 7MM
• Degenerative Disc Disease Companies- Mesoblast, Ltd., Grünenthal, DiscGenics, Inc., Spine Biopharma, Yuhan Corp, BioRestorative Therapies, AnGes, Inc., Shionogi & Co., Ltd., Kuros Biosurgery AG, Creative Medical Technology Holdings Inc., Stayble Therapeutics, Citospin, and others.
• Degenerative Disc Disease Therapies- Rexlemestrocel-L (MPC-06-ID), IDCT (Rebonuputemcel), SB-01 (Peniel2000/P2K, YH14618), BRTX-100, AMG0103 (NF-κB decoy oligonucleotide), and others.
• Degenerative Disc Disease Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Degenerative Disc Disease Unmet Needs, KOL’s views, Analyst’s views, Degenerative Disc Disease Market Access and Reimbursement

 

Download the report to understand which factors are driving Degenerative Disc Disease Market Trends @ Degenerative Disc Disease Market Trends

 

Table of Content

1 Key Insights

2 Report Introduction

3 Degenerative Disc Disease (DDD) Market Overview at a Glance

4 Epidemiology and Market Methodology of DDD

5 Executive Summary of Degenerative Disc Disease (DDD)

6 Key Events

7 Degenerative Disc Disease (DDD) Background and Overview

8 Epidemiology and Patient Population

9 Patient Journey

10 Emerging Therapies

11 DDD: Market Analysis

12 Key Opinion Leaders’ Views

13 SWOT Analysis

14 Unmet Needs

15 Market Access and Reimbursement

16 Appendix

17 DelveInsight Capabilities

18 Disclaimer

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/